CADL
MaterialsCandel Therapeutics Inc
Live · NASDAQ · May 9, Close
What's Moving CADL Today?
No stock-specific AI insight has been generated for CADL yet. Check back soon — insights are generated from recent news analysis.
Fundamentals
Trading
CADL News
20 articles- Candel Therapeutics to Host Investor Conference Call Following Presentation of Extended Data from Phase 3 Trial of Aglatimagene Besadenovec in Localized Prostate Cancer at the American Urological Association 2026 Annual MeetingYahoo Finance·May 4, 2026
- Candel Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)Yahoo Finance·May 1, 2026
- Candel Therapeutics teams up with EVERSANA to prep for prostate cancer drug launchProactive Investors·Apr 29, 2026
- Candel Therapeutics Announces Commercialization Agreement with EVERSANA to Support Potential U.S. Launch of Aglatimagene Besadenovec in Localized Prostate CancerYahoo Finance·Apr 29, 2026
- Candel Therapeutics reports extended survival in Phase 2a lung cancer trial of CAN-2409Proactive Investors·Mar 17, 2026
- Candel Therapeutics Reports Extended Survival Tail Observed in Trial of Aglatimagene Besadenovec (CAN-2409) in Advanced Non-Small Cell Lung Cancer Patients with Inadequate Response to Immune Checkpoint InhibitorsYahoo Finance·Mar 17, 2026
- Candel Therapeutics strengthens balance sheet as lead cancer therapy advancesProactive Investors·Mar 12, 2026
- Candel Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Corporate HighlightsYahoo Finance·Mar 12, 2026
- Candel Therapeutics To Present New Data after Extended Follow Up from Randomized Phase 3 Trial of Aglatimagene Besadenovec in Localized Prostate Cancer at the American Urological Association 2026 Annual MeetingYahoo Finance·Mar 9, 2026
- Candel Therapeutics to Present at TD Cowen’s 46th Annual Health Care Conference in BostonYahoo Finance·Feb 24, 2026
- Candel Therapeutics prices $100M public offeringProactive Investors·Feb 20, 2026
- Candel Therapeutics Announces Pricing of Public OfferingYahoo Finance·Feb 20, 2026
- Candel Therapeutics inks $100M funding agreement with RTW Investments, launches $100M public offeringProactive Investors·Feb 19, 2026
- Candel Therapeutics Announces Proposed $100 Million Public OfferingYahoo Finance·Feb 19, 2026
- Candel Therapeutics Announces $100M Royalty Funding Agreement with RTW to Support the Potential Launch of Aglatimagene Besadenovec (CAN-2409) in Localized Prostate CancerYahoo Finance·Feb 19, 2026
- Candel Therapeutics to Present at the 7th Annual Glioblastoma Drug Development SummitYahoo Finance·Feb 11, 2026
- Oncolytic Virus Clinical Trial Landscape Gains Momentum: 100+ Companies Lead the Charge in Pioneering New Treatments | DelveInsightYahoo Finance·Feb 4, 2026
- Loss-Making Candel Therapeutics, Inc. (NASDAQ:CADL) Expected To Breakeven In The Medium-TermYahoo Finance·Jan 14, 2026
- Candel Therapeutics to Host Virtual R&D Event on December 5, 2025Yahoo Finance·Nov 17, 2025
- Candel Therapeutics Reports Third Quarter 2025 Financial Results and Recent Corporate HighlightsYahoo Finance·Nov 13, 2025
All 20 articles loaded
Price Data
Fundamentals
Trading
About Candel Therapeutics Inc
Candel Therapeutics Inc is a clinical stage biopharmaceutical company focused on developing off-the-shelf viral immunotherapies that elicit an individualized, systemic anti-tumor immune response to help patients fight cancer. The immune cells induced by these viral immunotherapies are believed to target patients' specific tumor antigens, potentially improving responses in immunologically hot tumors while at the same time infiltrating the tumor microenvironment, transforming non-inflamed cold tumors with limited immune response into hot tumors. The company has established two clinical off-the-shelf viral immunotherapy platforms based on novel, genetically modified adenovirus and herpes simplex virus (HSV) constructs, respectively.